Pain management using nanotechnology approaches
Source abstract
Abstract
The proper treatment of pain is yet a major medical challenge. To obtain a long-term analgesia action, opioid therapy is the gold standard therapy for overcoming a chronic pain. Nanotechnology focus on formulating therapeutic agents encapsulated in a biocompatible nanocarriers (∼10-200 nanometer), these include but not limited to nanoparticles, liposomes and nanocapsules, micelles, dendrimers and nanotubes. This review gives an overview of current strategies of pain treatment with the help of the knowledge of nanotechnology. In addition, the applications of nano-innovation in oxidative therapy, genotoxicity and immunogenicity, are elucidated.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Anesthesiology, Faculty of Medicine, Lorestan University of Medical Sciences
Student Research Committee, Lorestan University of Medical Sciences
References (84)
Show source-provided references
1. 10.1016/j.yrtph.2012.11.00710.1016/j.yrtph.2012.11.007 ↗
2. 10.1515/epoly-2014-019810.1515/epoly-2014-0198 ↗
3. 10.1007/s00521-016-2212-010.1007/s00521-016-2212-0 ↗
4. 10.1007/s12221-014-0767-x10.1007/s12221-014-0767-x ↗
5. 10.1007/s11051-014-2622-910.1007/s11051-014-2622-9 ↗
6. 10.7314/APJCP.2013.14.5.333710.7314/APJCP.2013.14.5.3337 ↗
7. Barkin RL. The pharmacology of topical analgesics. Postgrad Med. 2013;125(suppl. 1).
8. Momenzadeh S, Moradkhani M, Moghadam MH. Low Level Laser Therapy (LLLT) combined with physical exercise, a more effective treatment in low back pain. J Lasers Med Sci. 2012;3:67.
9. 10.2174/1872213X0866614051515283710.2174/1872213X08666140515152837 ↗
10. 10.1136/annrheumdis-2012-20272610.1136/annrheumdis-2012-202726 ↗
11. 10.1615/CritRevTherDrugCarrierSyst.v23.i4.1010.1615/CritRevTherDrugCarrierSyst.v23.i4.10 ↗
12. 10.1016/j.coph.2012.10.00310.1016/j.coph.2012.10.003 ↗
13. 10.1016/j.addr.2012.03.00610.1016/j.addr.2012.03.006 ↗
14. 10.1038/3841010.1038/38410 ↗
15. 10.1021/cr800409e10.1021/cr800409e ↗
16. 10.1016/j.ces.2012.05.03510.1016/j.ces.2012.05.035 ↗
17. 10.1016/j.jscs.2015.11.00110.1016/j.jscs.2015.11.001 ↗
18. Mardani M. Wound antiseptic plants: an overview of the most important medicinal plants in iran affecting wound infections. J Glob Pharma Technol. 2017;8(8):18–23.
19. 10.1016/j.matlet.2011.08.01610.1016/j.matlet.2011.08.016 ↗
20. 10.1016/j.apcatb.2014.07.00910.1016/j.apcatb.2014.07.009 ↗
21. 10.1039/C3NR04490D10.1039/C3NR04490D ↗
22. Mardani M, Mahmoud B, Moradmand JS, et al. Comparison of the descurainia sophia and levostatin effect on the ldl cholesterol reduction, a clinical trial study. J Chem Pharm Sci. 2016;9:1329–1333.
23. Rezapour S, Ghahremani E, Mardani M. Analysis of antibiotic resistance and antimicrobial effects of Enterococcus faecium and Lactococcus lactis isolated from Khorramabad traditional cheeses. J Appl Biotechnol Rep. 2015;2:211–214.
24. 10.1016/j.jelechem.2012.07.00610.1016/j.jelechem.2012.07.006 ↗
25. 10.1016/j.snb.2014.11.02110.1016/j.snb.2014.11.021 ↗
26. 10.1007/s10904-013-9882-110.1007/s10904-013-9882-1 ↗
27. 10.1016/j.apcata.2012.12.00510.1016/j.apcata.2012.12.005 ↗
28. 10.1016/j.radphyschem.2012.02.03810.1016/j.radphyschem.2012.02.038 ↗
29. 10.1016/j.matlet.2012.02.02510.1016/j.matlet.2012.02.025 ↗
30. 10.1021/ja505429f10.1021/ja505429f ↗
31. Yousaf SA, Ali S. The effect of fluorine doping on optoelectronic properties of tin-dioxide (F: SnO2) thin films. Pak J Sci Ind Res. 2009;48:43–50.
32. Moradkhani MR, Karimi A. Role of drug anesthesia and cancer. Drug Res (Stuttg). 2017;68(3):125–131.
33. 10.1016/j.apcata.2014.03.01410.1016/j.apcata.2014.03.014 ↗
34. 10.1016/j.ijpharm.2013.05.02210.1016/j.ijpharm.2013.05.022 ↗
35. 10.1016/j.critrevonc.2013.06.01010.1016/j.critrevonc.2013.06.010 ↗
36. 10.1007/s11095-011-0558-710.1007/s11095-011-0558-7 ↗
37. 10.1007/s11095-012-0961-810.1007/s11095-012-0961-8 ↗
38. 10.1016/j.jconrel.2012.11.00510.1016/j.jconrel.2012.11.005 ↗
39. 10.1126/scitranslmed.300365110.1126/scitranslmed.3003651 ↗
40. 10.1002/anie.20140336710.1002/anie.201403367 ↗
41. 10.3109/03639045.2012.68439010.3109/03639045.2012.684390 ↗
42. 10.3109/1061186X.2014.99409710.3109/1061186X.2014.994097 ↗
43. 10.1016/j.ijpharm.2014.04.07110.1016/j.ijpharm.2014.04.071 ↗
44. 10.1016/j.biopha.2015.01.02210.1016/j.biopha.2015.01.022 ↗
45. 10.1007/s00345-013-1059-610.1007/s00345-013-1059-6 ↗
46. 10.1186/ar116910.1186/ar1169 ↗
47. Prasad PN. Nanotechnology for biophotonics: bionanophotonics. Introd to Biophotonics. 2004;15:520–544.
48. 10.1007/978-1-62703-475-3_1710.1007/978-1-62703-475-3_17 ↗
49. 10.1021/ar300022h10.1021/ar300022h ↗
50. 10.1007/s00204-012-0938-810.1007/s00204-012-0938-8 ↗
51. 10.5402/2012/13728910.5402/2012/137289 ↗
52. 10.3109/17435390.2013.77346410.3109/17435390.2013.773464 ↗
53. 10.5742/MEWFM.2017.9298210.5742/MEWFM.2017.92982 ↗
54. Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013;15:520–544.
55. Portillo J, Kamar N, Melibary S, et al. Safety of liposome extended-release bupivacaine for postoperative pain control. Front Pharmacol. 2014;30(5):90.
56. 10.1097/GOX.000000000000035510.1097/GOX.0000000000000355 ↗
57. 10.1055/s-0043-11718010.1055/s-0043-117180 ↗
58. Beiranvand S, Moradkhani MR. Bupivacaine versus liposomal bupivacaine for pain control. Drug Res (Stuttg). 2017;68(7):365–369.
59. 10.1093/asj/sjv14910.1093/asj/sjv149 ↗
60. 10.3928/01477447-20160315-0310.3928/01477447-20160315-03 ↗
61. 10.1097/PEC.000000000000138910.1097/PEC.0000000000001389 ↗
62. 10.15171/jnp.2017.3410.15171/jnp.2017.34 ↗
63. Hassan SS, Carlson K, Mohanty SK, et al. Ultra-rapid catalytic degradation of 4-nitrophenol with ionic liquid recoverable and reusable ibuprofen derived silver nanoparticles. Environ Pollut. 2017;4:731–739.
64. 10.1080/21691401.2017.131326510.1080/21691401.2017.1313265 ↗
65. Moradkhani MR, Karimi A, Negahdari B. Nanotechnology application to local anaesthesia (LA). Artif cells, nanomedicine Biotechnol. 2017;46:1–6.
66. Chakravarthy KV, Boehm FJ, Christo PJ. Nanotechnology: a promising new paradigm for the control of pain. Pain Med. 2017;89:0749–5161.
67. 10.1016/j.jpain.2017.02.06410.1016/j.jpain.2017.02.064 ↗
68. Vahabi S, Beiranvand S. Effect of local ropivacaine on hemodynamic responses in craniotomy patients. J Investig Surg. 2017;32:1–5.
69. 10.1055/s-0043-11853710.1055/s-0043-118537 ↗
70. 10.1016/j.ijpharm.2016.11.01610.1016/j.ijpharm.2016.11.016 ↗
71. Ghafarzadeh M, Namdari P, Tarhani M, et al. A review of application of stem cell therapy in the management of congenital heart disease. J Matern Neonatal Med. 2018;33:1–9.
72. 10.1016/j.stemcr.2015.01.00510.1016/j.stemcr.2015.01.005 ↗
73. 10.1016/j.addr.2008.03.01410.1016/j.addr.2008.03.014 ↗
74. 10.1016/j.biopha.2017.01.17110.1016/j.biopha.2017.01.171 ↗
75. 10.1080/08941939.2017.129981910.1080/08941939.2017.1299819 ↗
76. 10.1088/0957-4484/25/45/45200110.1088/0957-4484/25/45/452001 ↗
77. 10.1016/j.peptides.2012.03.02110.1016/j.peptides.2012.03.021 ↗
78. 10.1016/j.nano.2011.05.01310.1016/j.nano.2011.05.013 ↗
79. 10.1016/j.ejps.2013.05.01410.1016/j.ejps.2013.05.014 ↗
80. 10.1016/j.jconrel.2012.02.02710.1016/j.jconrel.2012.02.027 ↗
81. 10.1208/s12248-012-9433-710.1208/s12248-012-9433-7 ↗
82. 10.1016/j.leukres.2012.07.00610.1016/j.leukres.2012.07.006 ↗
83. 10.1007/s10637-011-9709-210.1007/s10637-011-9709-2 ↗
84. 10.1016/j.ejpb.2011.10.00310.1016/j.ejpb.2011.10.003 ↗